SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 3

Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies

Zouina SARFRAZ
Azza SARFRAZ
Muzna SARFRAZ
Hinna AFTAB
Zainab PERVAIZ
Pages
890–897
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.Key words: Tocilizumab, actemra, coronavirus, COVID-19, clinical trial, cytokine storm syndrome

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged.
📊
Key Findings & Data:The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored.
💡
Conclusion & Impact:Conclusion: This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.Key words: Tocilizumab, actemra, coronavirus, COVID-19, clinical trial, cytokine storm syndrome
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored. Materials and methods: A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials. Results: A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was conducted. Conclusion: This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.Key words: Tocilizumab, actemra, coronavirus, COVID-19, clinical trial, cytokine storm syndrome

🔖

Cite This Article

SARFRAZ, Z., SARFRAZ, A., SARFRAZ, M., AFTAB, H., PERVAIZ, Z. (2022). Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 3, 890–897. https://ajindex.com/articles/609591

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bryant F. COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. The Lancet Rheumatology 2020
  2. 2 (10): e592. doi: 10.1016/S2665-9913(20)30313-1 2. World Health Organisation. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019- nCoV) Infection is Suspected: Interim Guidance. WHO. 2020. 3. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y et al. Pharmaco-immunomodulatory therapy in COVID-19. Drugs 2020
  3. 80 (13): 1267-1292. doi: 10.1007/s40265-020-01367-z 4. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2020
  4. 2 (8): e474-e484. doi: 10.1016/S2665-9913(20)30173-9 5. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European Journal of Internal Medicine 2020
  5. doi: 10.1016/j. ejim.2020.05.009 6. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child and Adolescent Health 2020
  6. 4 (9): 653-661. doi: 10.1016/S2352-4642(20)30177-2 7. Roumier M, Paule R, Vallée A, Rohmer J, Ballester M et al. Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis. Journal of Clinical Immunology 2020
  7. doi: 10.1007/s10875-020-00911-6 8. Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K et al. Tocilizumab for the treatment of severe coronavirus disease 2019. Journal of Medical Virology 2020
  8. 92 (10): 2042-2049. doi: 10.1002/jmv.25964 9. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine 2020
  9. doi: 10.1016/j. ejim.2020.05.021 10. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases 2020
  10. doi: 10.1093/cid/ciaa954 11. Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. Journal of Internal Medicine 2020. doi: 10.1111/joim.13162 12. Wadud N, Ahmed N, Mannu Shergil M, Khan M, Krishna MG et